淋巴瘤疗效评估中的中期FDG-PET/CT
综述探讨中期FDG-PET/CT(iPET/CT)在淋巴瘤疗效评估中的临床应用与预后价值。经典型霍奇金淋巴瘤(cHL)中iPET/CT引导的反应适应治疗已是广泛使用的一线标准治疗;非霍奇金淋巴瘤(NHL)中证据尚不充分,但未达到完全代谢缓解通常被视为不良预后因素。
要点
- cHL中iPET/CT引导的反应适应治疗是广泛使用的一线标准治疗。
- NHL中iPET/CT证据尚不充分,未达完全代谢缓解通常为不良预后因素。
- 综述涵盖cHL及DLBCL、FL、PTCL等NHL亚型的主要iPET反应适应临床试验。
核心结论
- iPET/CT的临床使用和预后价值因淋巴瘤亚型而异,cHL证据更充分,NHL证据尚不充分。
研究设计与样本
- 本文为综述,汇总支持iPET/CT用于淋巴瘤患者的现有证据,重点讨论cHL及DLBCL、FL、PTCL等NHL亚型的主要iPET反应适应临床试验并提及正在进行的试验。
主要发现
- cHL中支持iPET/CT预后价值的证据更充分,iPET/CT引导的反应适应治疗是广泛使用的一线标准治疗。
- NHL中支持iPET/CT使用的数据尚不充分,但iPET/CT未达到完全代谢缓解通常被视为不良预后因素,可能影响无进展生存。
临床怎么用
- cHL一线治疗中,iPET/CT引导的反应适应治疗是广泛使用的标准治疗。
- NHL中iPET/CT未达到完全代谢缓解通常被视为不良预后因素,可能影响无进展生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clinical use and prognostic value of interim FDG-PET/CT (iPET/CT), which is performed after treatment initiation but prior to its completion, varies by lymphoma subtype. Evidence supporting the prognostic value of iPET/CT is more robust for classical Hodgkin lymphoma (cHL), and in this lymphoma subtype, response-adapted treatment approaches guided by iPET/CT are a widely used standard of care for first-line therapy. The data supporting use of iPET/CT among patients with non-Hodgkin lymphoma (NHL) is less well-established, but failure to achieve complete metabolic response on iPET/CT is generally considered a poor prognostic factor with likely consequences for progression free survival. This review will present the available evidence supporting use of iPET/CT in lymphoma patients, particularly as it relates to prognostication and the ability to inform response-adapted treatment strategies. The latter will be addressed through a discussion on the major iPET-response adapted clinical trials with mention of ongoing trials. Special attention will be given to cHL and a few subtypes of NHL, including diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), and peripheral T cell lymphoma (PTCL).
引用
- Zeman MN, Akin EA, Merryman RW, et al. Interim FDG-PET/CT for Response Assessment of Lymphoma. Semin Nucl Med. 2022. PMID: 36376131. doi:10.1053/j.semnuclmed.2022.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。